乳腺癌风险建模方面的进展:整合诊所,成像,病理学和人工智能,以进行个性化风险评估
Filippo Pesapane1, Ottavia Battaglia2, Giuseppe Pellegrino2
1Breast Imaging Division, IEO European Institute of Oncology IRCCS, Milan, 20141, Italy.
Future oncology (London, England)
|December 12, 2023
概括
乳腺癌风险模型使用各种风险因素预测患乳腺癌的可能性. 整合多样化的数据源可以增强个性化的预防和早期检测策略.
科学领域:
- 在瘤学瘤学.
- 医疗成像医学成像
- 遗传学 是一个遗传学.
背景情况:
- 乳腺癌风险模型评估个人的患病可能性.
- 放射科医生确定的乳房扫描密度是一个关键的危险因素.
- 个性化干预和查计划对于改善结果至关重要.
研究的目的:
- 探索乳腺癌风险建模的组成部分和进展.
- 突出多学科数据整合在提高模型准确性的作用.
- 讨论乳腺癌风险评估中的挑战和未来方向.
主要方法:
- 风险因素的审查,包括乳房扫描密度,临床数据和遗传信息.
- 整合来自放射学,病理学和临床评估的数据.
- 人工智能 (AI) 在乳房镜中用于数据集成和模型开发的应用.
主要成果:
- 乳房图像密度是通过先进成像识别的显著风险因素.
- 瘤遗传检测和分子分析提高了风险评估的准确性.
- 人工智能整合了各种数据 (成像,临床,遗传,病理) 用于复杂的风险模型.
结论:
- 结合成像,病理学,遗传学和临床数据的多学科方法至关重要.
- 新兴技术显著提高了乳腺癌风险模型的准确性和实用性.
- 改进的风险模型有助于早期发现乳腺癌和个性化预防策略.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Survival Analysis
355
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
355


